Stockscreener 앱 받기
317.36
3.29%
-10.80
시간 외 거래:
315.80
-1.56
-0.49%
전일 마감가:
$328.16
열려 있는:
$327.1
하루 거래량:
815.16K
Relative Volume:
0.62
시가총액:
$42.09B
수익:
$3.71B
순이익/손실:
$313.75M
주가수익비율:
140.61
EPS:
2.2571
순현금흐름:
$465.38M
1주 성능:
+1.66%
1개월 성능:
-4.67%
6개월 성능:
-28.91%
1년 성능:
+17.10%
1일 변동 폭
$316.85
$329.69
1주일 범위
$299.62
$332.81
52주 변동 폭
$205.87
$495.55
Alnylam Pharmaceuticals Inc Stock (ALNY) Company Profile
명칭
Alnylam Pharmaceuticals Inc
전화
(617) 551-8200
주소
675 WEST KENDALL STREET, CAMBRIDGE, MA
Compare ALNY vs VRTX, REGN, ARGX, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ALNY
Alnylam Pharmaceuticals Inc
|
317.36 | 42.09B | 3.71B | 313.75M | 465.38M | 2.2571 |
VRTX
Vertex Pharmaceuticals Inc
|
433.07 | 110.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
737.71 | 77.99B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
691.40 | 42.91B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
283.03 | 31.42B | 5.36B | 287.73M | 924.18M | 2.5229 |
Alnylam Pharmaceuticals Inc Stock (ALNY) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-16 | 다운그레이드 | Jefferies | Buy → Hold |
| 2026-01-28 | 재개 | Barclays | Overweight |
| 2026-01-07 | 재개 | Oppenheimer | Outperform |
| 2025-08-04 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2025-08-04 | 업그레이드 | Wolfe Research | Underperform → Peer Perform |
| 2025-07-30 | 재개 | Raymond James | Outperform |
| 2025-07-21 | 개시 | Truist | Buy |
| 2025-03-31 | 개시 | Redburn Atlantic | Buy |
| 2025-03-24 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2024-11-12 | 다운그레이드 | Wolfe Research | Peer Perform → Underperform |
| 2024-10-16 | 개시 | Scotiabank | Sector Outperform |
| 2024-08-16 | 업그레이드 | Goldman | Neutral → Buy |
| 2024-02-16 | 다운그레이드 | Goldman | Buy → Neutral |
| 2024-02-15 | 개시 | Wolfe Research | Peer Perform |
| 2023-12-08 | 개시 | Wells Fargo | Equal Weight |
| 2023-10-11 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2023-09-29 | 개시 | Raymond James | Outperform |
| 2023-05-05 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-26 | 개시 | SMBC Nikko | Neutral |
| 2023-03-21 | 개시 | Bernstein | Outperform |
| 2023-01-18 | 개시 | Canaccord Genuity | Buy |
| 2022-09-09 | 재개 | Morgan Stanley | Equal-Weight |
| 2022-07-13 | 개시 | Cantor Fitzgerald | Neutral |
| 2022-06-27 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2022-06-07 | 개시 | William Blair | Outperform |
| 2022-04-25 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2022-03-01 | 개시 | Citigroup | Buy |
| 2022-02-03 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2022-01-03 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2021-11-22 | 업그레이드 | Goldman | Neutral → Buy |
| 2021-11-22 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-11-01 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2021-10-04 | 업그레이드 | UBS | Neutral → Buy |
| 2021-08-04 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2021-02-22 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2021-02-12 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2021-02-12 | 재확인 | H.C. Wainwright | Buy |
| 2021-01-25 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-30 | 재개 | Berenberg | Hold |
| 2020-09-08 | 개시 | Citigroup | Buy |
| 2020-08-11 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2020-05-13 | 개시 | RBC Capital Mkts | Sector Perform |
| 2020-05-07 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-04-24 | 재개 | Evercore ISI | Outperform |
| 2020-03-19 | 개시 | Berenberg | Buy |
| 2019-12-19 | 재확인 | Chardan Capital Markets | Buy |
| 2019-11-20 | 개시 | Oppenheimer | Outperform |
| 2019-11-13 | 개시 | BofA/Merrill | Buy |
| 2019-05-23 | 재개 | Goldman | Neutral |
| 2019-04-12 | 개시 | Evercore ISI | Outperform |
| 2019-03-06 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2019-03-05 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2019-01-23 | 개시 | UBS | Neutral |
| 2018-10-01 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-08-13 | 재확인 | Stifel | Buy |
| 2018-08-07 | 업그레이드 | Stifel | Hold → Buy |
| 2018-05-04 | 재확인 | Stifel | Hold |
| 2018-03-28 | 개시 | Evercore ISI | In-line |
모두보기
Alnylam Pharmaceuticals Inc 주식(ALNY)의 최신 뉴스
How Alnylam Pharmaceuticals Inc. (ALNY) Affects Rotational Strategy Timing - Stock Traders Daily
Assenagon Asset Management S.A. Sells 54,791 Shares of Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
The European Commission Approves Alnylam’s AMVUTTRA - MSN
Alnylam Pharmaceuticals, Inc. (ALNY) Discusses Progress and Strategy in Transforming ATTR Amyloidosis Care and Expanding TTR FranchiseSlideshow (NASDAQ:ALNY) 2026-03-26 - Seeking Alpha
Vanguard amends 13G/A; reports 0 shares in Alnylam (ALNY) - Stock Titan
3 Stocks Trading Below Estimated Intrinsic Value By Up To 46.8% - simplywall.st
H.C. Wainwright reiterates Alnylam stock rating at buy, $510 target - Investing.com
SG Americas Securities LLC Buys 59,071 Shares of Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Alnylam (ALNY) Targets 25% CAGR with Innovative Therapies - Insider Monkey
Alnylam (ALNY) jumps 6.7% as investors refocus on TTR franchise after company webinar - Quiver Quantitative
Chardan Capital Reaffirms "Buy" Rating for Alnylam Pharmaceuticals (NASDAQ:ALNY) - MarketBeat
ALNY: HC Wainwright & Co. Reiterates Buy Rating with $510 Target - GuruFocus
Alnylam Pharmaceuticals (NASDAQ:ALNY) Given "Buy" Rating at HC Wainwright - MarketBeat
10 Health Care Stocks With Whale Alerts In Today's Session - Benzinga
Assessing Alnylam Pharmaceuticals (ALNY) Valuation After Recent Share Price Weakness - simplywall.st
Alnylam Ties AI Partnerships To ATTR CM Growth And Access Story - Yahoo Finance
Alnylam teams up with Viz.ai and American Heart Association to advance ATTR-CM care - MSN
Narrow-Moat Alnylam's Growth Driven By Strong Demand For Amvuttra in ATTR-CM - Morningstar
Immutrin raises $87M to advance drug for progressive heart disease - BioPharma Dive
Morgan Stanley reiterates Alnylam stock Equalweight rating at $360 - Investing.com
Alnylam Pharmaceuticals Touts AMVUTTRA ATTR-CM Momentum, Raises 2026 TTR Revenue Outlook - Yahoo Finance
Alnylam Advances Future of ATTR-CM Care Through Strategic Collaboration with Viz.ai and Support for the American Heart Association - Business Wire
Viz.ai Partners with Alnylam Pharmaceuticals to Advance Earlier Identification and Care Coordination in Cardiac Amyloidosis - Business Wire
Alnylam partners with Viz.ai, AHA on ATTR-CM diagnosis efforts - Investing.com
Congress Asset Management Co. Boosts Position in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Hudson Bay Capital Management LP Lowers Holdings in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Chart Watch: Does Alnylam Pharmaceuticals Inc have a sustainable dividend2026 EndofYear Setup & Weekly High Return Forecasts - baoquankhu1.vn
Growth Review: What analysts say about Alnylam Pharmaceuticals Inc stockQuarterly Performance Summary & High Accuracy Investment Entry Signals - baoquankhu1.vn
Alnylam’s research pact worth up to $1.1B sends Tenaya higher - MSN
Alnylam Pharmaceuticals (ALNY) reports $3B 2025 revenue driven by 151% TTR franchise surge - MSN
Alnylam Pharmaceuticals (NASDAQ:ALNY) Downgraded by Wall Street Zen to "Hold" - MarketBeat
Polar Asset Management Partners Inc. Reduces Holdings in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Alnylam and Tekmira Restructure Relationship and Settle All Litigation - Yahoo
Alnylam’s Cardiovascular RNAi Collaboration With Tenaya Might Change The Case For Investing In ALNY - Sahm
Can Alnylam's Pipeline Medications Drive Sustainable Growth in the Future? - Bitget
Can Alnylam's Pipeline Drugs Sustain Long-Term Growth Ahead? - The Globe and Mail
Novartis acquisition spin-off pioneers RNA therapeutics for the heart - Pharma Voice
Groupama Asset Managment Purchases 2,483,697 Shares of Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
CIBC Private Wealth Group LLC Reduces Position in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
1ALNY.MI Stock Price, Quote & Chart | ALNYLAM PHARMACEUTICALS INC (BIT:1ALNY) - ChartMill
Canaccord Genuity maintains buy rating on Alnylam Pharmaceuticals, Inc. (ALNY) stock - MSN
Alnylam Pharmaceuticals Q2 2025 Earnings Preview - MSN
Here's How Much You Would Have Made Owning Alnylam Pharmaceuticals Stock In The Last 20 Years - Benzinga
The $3B Biotech With Two Shots On Goal - Benzinga
Linden Advisors LP Makes New $6.55 Million Investment in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Short Interest Down 12.8% in February - MarketBeat
Brevan Howard Capital Management LP Buys Shares of 6,170 Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Jefferies downgrades Alnylam Pharmaceuticals (ALNY) - MSN
California Public Employees Retirement System Buys 18,060 Shares of Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Bamco Inc. NY Acquires New Shares in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
(ALNY) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Alnylam Pharmaceuticals Inc (ALNY) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.21%
2.20%
자본화:
|
볼륨(24시간):